1. Generics Bulletin
  2. >>Products
  3. >>Generics

Efforts Made Across Off-Patent Industry To Secure Ukrainian Medicines Supply

Medicines For Europe Has Called For Humanitarian Corridors To Remain Open

 
• By Chloe Kent

As the invasion of Ukraine continues, trade bodies, manufacturers and individuals across the off-patent industry have stepped up to try and maintain supply of essential medicines to the region.

Woman with Ukraine flag painted on cheek protesting Russian invasion
Efforts have been made across the off-patent industry to support people in Ukraine • Source: Alamy

Off-patent trade association Medicines for Europe has committed to providing medicines on humanitarian grounds to all those in need impacted by the Russian invasion of Ukraine. The conflict is now entering its third week. The priority for its members, Medicines for Europe said, is “to continue to ensure that patients in Ukraine and refugees arriving in EU member states have access to the medicines and medical materials they need.”

Medicines for Europe is engaging with authorities and non-governmental organizations on the ground to ensure ongoing access to medicines and medical supplies. It is in contact with the Ukrainian government and companies operating in the country to assess what medicines are needed and to request supplies from its member companies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Hikma Eyes $5bn Sales Target As It Sets Out Plans To 2030

 
• By Dave Wallace

Unveiling a new name for its generics business, Hikma has at the same time set out medium-term financial goals for its business that include three-year growth objectives for its sales and profits, as well as aiming at a $5bn turnover target by 2030.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

More from Products

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.